Navigation Links
Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
Date:6/2/2008

CHICAGO and REGENSBURG, Germany, June 2 /PRNewswire/ -- The TGF-beta 2 inhibitor AP 12009, developed by Antisense Pharma, reveals very good safety and tolerability in the systemic treatment of pancreatic carcinoma, malignant melanoma and colorectal carcinoma. AP 12009, administered intravenously, showed a clear proof of concept. Patients with stage IV pancreatic carcinoma, who received AP 12009 for seven days every other week as second or third line therapy, had a median survival time of 29.6 weeks (6.8 months) after start of AP 12009 treatment. One of these patients with several liver metastases even experienced a complete response. Efficacy and safety results of the multicenter Phase I/II study were published today at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA (1).

In the open-label, multicenter, dose-escalation Phase I/II study patients with advanced stage pancreatic carcinoma, malignant melanoma or colorectal carcinoma were included. So far 25 patients have been treated in six cohorts. The first four cohorts received AP 12009 as 7-day on, 7-day off cycles. For this schedule, the maximum tolerated dose (MTD) was reached with two grade III thrombocytopenias as dose-limiting toxicities (DLT). These were self-limiting and required no therapeutic intervention. The third DLT was a grade III rash. Thus, the compound AP 12009 revealed excellent safety and tolerability. Very encouraging case reports were observed. One patient, diagnosed with stage IV malignant melanoma, survived more than 60 weeks after the start of AP 12009 treatment. Another patient with stage IV pancreatic carcinoma and several liver metastases had a complete response and is still alive as of March 2008 148 weeks (34 months) after the start of treatment with AP 12009.

After reaching the MTD with the 7-day on, 7-day off schedule, a second schedule with 4-day on, 10-day off cycles was initiated. Two cohorts with a total of seven patients h
'/>"/>

SOURCE Antisense Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
2. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
3. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
4. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
5. Amikacin Inhale Shows Promising Results in Phase II Study
6. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
7. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
8. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
9. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
10. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
11. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Texas , Sept. 17, 2014  Lightbeam ... Direct Accountable Care Organization (Physician Direct ACO) to ... their physicians in providing better care while reducing ... Physician Direct Accountable Care Organization ... Network Services (OPNS). The OPNS mission is to ...
(Date:9/17/2014)... -- An analysis done by the CVS Health Research ... new and expensive treatment for Hepatitis C introduced in ... months (May through August 2014) there has been a ... suggests another surge of patients will begin therapy when ... and shorter duration are introduced in the Fall. ...
(Date:9/17/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... public offering of 4,500,000 shares of its common stock at ... share. Aratana has granted the underwriters a 30-day ... shares of its common stock. Jefferies ...
Breaking Medicine Technology:Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
... Synteract, Inc ., a full-service contract ... training classes for CDISC , a global, ... the acquisition, exchange, submission and archive of clinical ... 21-24, 2012 at Synteract,s Carlsbad, Calif., headquarters. ...
... COLUMBUS, Ohio, Feb. 17, 2012  Chemical Abstracts Service ... Taylor & Francis, a leading publisher of scientific ... new experimental procedures for chemical reactions from three ... SciFinder®. (Logo: http://photos.prnewswire.com/prnh/20110418/MM84805 ) ...
Cached Medicine Technology:Synteract Hosting CDISC Classes on Regulatory Data Standards, Feb. 21-24, in California 2CAS and Taylor & Francis Collaborate to Improve Scientists' Access to Published Research 2
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 North ... were recently granted several awards for their top-notch services. ... patient experience, orthopedic care and GYN surgery. , Hospital-wide, ... Safety Excellence Award™. They have received this award for ... among the top 5 percent in the nation for ...
(Date:9/17/2014)... (HealthDay News) -- A blood test that measures DNA ... a better assessment of the state of a man,s ... routinely, this blood test could reveal when treatment ... promoting tumor growth, the researchers suggested. "Our study ... advanced prostate cancer and often initially very effective started ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... Why are Asian Americans at higher risk of developing ... develop the disease at lower body weights? One part ... traditional high-fiber, low-fat Asian diets to current westernized diets, ... heritage, says George King, M.D., Senior Vice President and ... senior author of the study. , A Joslin randomized ...
(Date:9/17/2014)... The in vitro diagnostics (IVD) marketplace is ... on molecular diagnostics for conditions such as infectious diseases, ... IVD market value is projected to be worth around ... major drivers of the market’s growth include the shift ... by the explosion for raid and minimally-invasive diagnostic tools; ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... countrymen safe drinking water within a matter of four ... // to make this possible. Most people living in ... water. ,Inaugurating a conference of ministers ... sanitation in states and union territories, the prime minister ...
... speak hundred words, these non-verbal communications is also found ... been a major cause of distress and may lead ... School of Medicine along with his colleagues from Indianapolis ... as reported in the Journal of General Internal Medicine ...
... Journal of the American Medical Association has published that ... continue their anti-depressant medication to avoid a relapse.// ... University and Massachusetts General Hospital, where 201 pregnant women ... not depressed during the course of the study. According ...
... Michael Horwin have launched the SV40 Cancer Foundation in ... 1999 from an SV40 positive brain tumor. // The ... encourage independent research and to facilitate clinical improvements." ... brain tumor that was caused by an active SV40 ...
... there is a definite link between disease and higher death rates ... the // data of 1,347 people aged about 56 in the ... ,The IQ of the volunteers was assessed by a written test ... scores follow a social trend and that the poorest socioeconomic groups ...
... revealed that a Husband’s comforting touch can be a ... the study, those who establish instant communication by reaching ... A handy tip on how human touch can alleviate ... feature of the study revealed that relief from a ...
Cached Medicine News:Health News:Safe Drinking Water To Be Made Available 2Health News:Pregnancy Not An Antidote To Depression 2Health News:Handy Touch - A Wand to Bust Stressful Situations 2
... Nebulizer Disposable Prefilled 28%-100% FIO 2 1000ML ... ,Our prefilled nebulizers provide unmatched performance and ease ... high-output aerosols adjustable from 28% to 100% FIO ... solutions: sterile water for inhalation, USP; 0.45% sodium ...
Respirgard II Nebulizer System with Acorn II Nebulizer, 7' (2 m) supply tubing, universal "antidrool" tee, mouthpiece, 6" (15 cm) aerosol tube, wye, one-way valve and expiratory filter...
... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
... modified nebulizer setups to deliver CNT and ... your patient is critical? OMNI~MAX has everything ... Heliox rescue therapy. In severe obstructive disease, ... of care in hospitals across the nation. ...
Medicine Products: